GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Total Payout Ratio

Arovella Therapeutics (ASX:ALA) Total Payout Ratio : 0.75 (As of May. 18, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Arovella Therapeutics's current Total Payout Ratio is 0.75.


Arovella Therapeutics Total Payout Ratio Historical Data

The historical data trend for Arovella Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Total Payout Ratio Chart

Arovella Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 - 1.95 0.73 0.54

Arovella Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.34 0.03 0.86 0.58

Competitive Comparison of Arovella Therapeutics's Total Payout Ratio

For the Biotechnology subindustry, Arovella Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arovella Therapeutics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's Total Payout Ratio falls into.



Arovella Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Arovella Therapeutics's Total Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 5.478 + 0) / -10.181
=0.54

Arovella Therapeutics's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0.112 + 2.402 + 0) / -3.946
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arovella Therapeutics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arovella Therapeutics (ASX:ALA) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton, WA, AUS, 3053
Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics (ASX:ALA) Headlines

No Headlines